Hepatitis C treatment completion rates in routine clinical care.
about
Barriers to hepatitis C treatmentResults of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection.HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeVirologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.High rates of early treatment discontinuation in hepatitis C-infected US veterans.A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study.Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment.The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES.Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort CollaborationThe high comorbidity burden of the hepatitis C virus infected population in the United States.Rate, delay and predictors of hepatitis C treatment in British ColumbiaAnemia management in the era of triple combination therapy for chronic HCV.Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues.Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease.Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response.A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veteransFactors associated with completion of a behavioral intervention for caregivers of urban children with asthma.Liver fibrosis progression in hepatitis C virus infection after seroconversionThe epidemiology of substance use disorders in US Veterans: A systematic review and analysis of assessment methods.Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection.Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs.Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C.The Rate of Referral of Hepatitis Virus Carriers to Hepatologists and the Factors Contributing to Referral.Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.Treatment of chronic hepatitis C in Croatian war veterans: experiences from Croatian reference center for viral hepatitis.All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia.
P2860
Q27012664-E1770D3C-5618-4528-80FA-E4BFA7493B0BQ30151392-9666140E-D789-4EEB-8EA5-AA3814425AC9Q30224806-E509E3B5-10CF-4339-85C2-526CCF875788Q31012317-38294384-72F7-4E18-8493-4161E87925B7Q33419423-53B95026-53C6-4372-98B0-B2EF3A21F4CDQ33574602-4EFA24B2-FC46-4F81-8A92-B0BE996B3F6AQ34322384-8175DFBC-4F68-4AFF-B3C4-0FB441934F5CQ34677310-21962C42-7162-4F94-AF80-E946BA5FED75Q35184927-72BA8F58-875B-48EA-A982-9A30735834C4Q35249642-7DB99D93-4EDD-4F8B-A3FC-38B613AD03F9Q35838417-E4BBC0BE-1589-4069-B7C2-136AF2029112Q35856799-AC638164-62A5-4341-9678-8D4373EBC5C1Q35864236-6C792EE6-92B3-4B42-B731-A52D89A035BBQ35927970-6BF416D5-5F20-48F4-B1F6-A2FC7E094A79Q36082161-0633AED2-07CB-42D1-8914-7793BEDD2AABQ36496953-ED5E248D-055C-4BE7-8735-A4F19281DBA6Q36531731-B8CAC2FC-E2F5-4DF2-B87D-C8D9B73C3184Q36933104-489FD97B-4739-41DB-ADD4-EBA6A6250AE4Q36942884-5788656D-0EA5-474A-8E0A-07D2118902E6Q36955116-7890F63C-ACC2-4D2B-97C1-51D5D459FD3FQ37035655-E089949B-59D7-44A0-9166-EC47BD98EFD4Q37172069-04AE39F7-0040-49FA-AC38-B08871803E5AQ37244507-8ACC1B51-E0A7-402B-9B40-185F3C2276ECQ37440320-8C80F255-CA0E-49E7-B98E-08F77878F9E6Q37731286-1FC0794D-9851-4E18-81F8-75B26AF0E339Q38323723-1FC03E39-D861-4932-A6C1-3F928AC145B3Q38933599-86BDC8D6-1D98-4A20-B2B0-22D33BB267E5Q39146830-4FEC10E4-63D6-4962-B796-15BE54F1E9ADQ40097439-D40F3EE7-F4F7-4064-80F1-3E78FFAFB990Q40428996-043113BC-6ECC-4326-A374-031A8E52B8BBQ40489570-78F3FD90-B4E2-4138-901B-2CFCA7EC5BC4Q40891023-BD0150AE-6CA3-48D9-89FD-724708DFAA48Q41486392-5CE8D2C1-12AD-46B3-95A1-136C34E298F7Q42090512-01856F6A-C490-417C-AEFA-6709F6DD8802Q42238837-2A374073-A4FE-4847-AD8F-55EE1A5227EBQ45306504-3F96F15C-DDF6-4A15-9FD2-F92511DBA007
P2860
Hepatitis C treatment completion rates in routine clinical care.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Hepatitis C treatment completion rates in routine clinical care.
@ast
Hepatitis C treatment completion rates in routine clinical care.
@en
type
label
Hepatitis C treatment completion rates in routine clinical care.
@ast
Hepatitis C treatment completion rates in routine clinical care.
@en
prefLabel
Hepatitis C treatment completion rates in routine clinical care.
@ast
Hepatitis C treatment completion rates in routine clinical care.
@en
P2093
P2860
P1433
P1476
Hepatitis C treatment completion rates in routine clinical care.
@en
P2093
Adeel A Butt
Amy C Justice
Kathleen A McGinnis
Melissa Skanderson
P2860
P304
P356
10.1111/J.1478-3231.2009.02156.X
P577
2009-11-04T00:00:00Z